Back to Journals » Therapeutics and Clinical Risk Management » Volume 11

Which people should take aspirin for primary prevention of cardiovascular disease?

Authors Lozano R, Franco ME

Received 6 May 2015

Accepted for publication 22 May 2015

Published 2 July 2015 Volume 2015:11 Pages 1043—1045

DOI https://doi.org/10.2147/TCRM.S88091

Checked for plagiarism Yes

Roberto Lozano,1 Maria-Esther Franco2

1Pharmacy Department, 2Haematology Department, Hospital Real de Nuestra Señora de Gracia, Zaragoza, Spain

Dear editor

A single trial, ISIS-2,1 in 1988, demonstrated the utility of daily aspirin in the setting of acute myocardial infarction, reducing the risk of vascular death by 23%. In addition, aspirin has also proven effective in the setting of acute ischemic stroke.2 Thus, for a subset of the general population, aspirin may help to prevent heart attacks and strokes. In fact, at low doses, in the range of 75 to 100 mg per day, aspirin prevents the progression of existing cardiovascular disease (CVD), including coronary heart disease, stroke and peripheral arterial disease, and reduces the frequency of cardiovascular events in patients with history of CVD,3,4 referred to as secondary prevention.
Although the benefits of aspirin for secondary prevention of CVD are well known, its use in primary prevention of CVD, defined as prevention of the first occurrence of CVD for all patients without clinical CVD, including those with diabetes mellitus and those without clinical evidence of atherosclerotic disease who are at higher CVD risk, is less clear and controversial results have been obtained. In fact, the results of several studies using aspirin for primary prevention of CVD have generally shown more modest reductions of major vascular events compared with secondary prevention (12% vs 23%).3,5



Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other articles by this author:

Influence of hypothyroidism on renal function of lithium-treated patients

Lozano R, Marín R, Santacruz MJ

Neuropsychiatric Disease and Treatment 2016, 12:25-27

Published Date: 23 December 2015

Analysis of the cumulative effect of schizophrenia-related single nucleotide polymorphisms

Lozano R, Marín R, Freire I, Santacruz MJ, Pascual-García A

Neuropsychiatric Disease and Treatment 2014, 10:1079-1080

Published Date: 12 June 2014

Atazanavir–bilirubin interaction: a pharmacokinetic–pharmacodynamic model

Lozano R, Domeque N, Apesteguia AF

Clinical Pharmacology: Advances and Applications 2013, 5:153-159

Published Date: 27 September 2013

The efficacy of Li in bipolar disorder

Lozano R, Marín R, Santacruz MJ, Freire I, Gomez R

Neuropsychiatric Disease and Treatment 2013, 9:953-954

Published Date: 11 July 2013

Reducing serum cholesterol levels in women

Lozano R

Neuropsychiatric Disease and Treatment 2012, 8:405-406

Published Date: 12 September 2012

Readers of this article also read:

Perioperative management of hemophilia patients receiving total hip and knee arthroplasty: a complication report of two cases

Tateiwa T, Takahashi Y, Ishida T, Kubo K, Masaoka T, Shishido T, Sano K, Yamamoto K

Therapeutics and Clinical Risk Management 2015, 11:1383-1389

Published Date: 15 September 2015

Quetiapine for acute bipolar depression: a systematic review and meta-analysis

Suttajit S, Srisurapanont M, Maneeton N, Maneeton B

Drug Design, Development and Therapy 2014, 8:827-838

Published Date: 25 June 2014

Green synthesis of water-soluble nontoxic polymeric nanocomposites containing silver nanoparticles

Prozorova GF, Pozdnyakov AS, Kuznetsova NP, Korzhova SA, Emel’yanov AI, Ermakova TG, Fadeeva TV, Sosedova LM

International Journal of Nanomedicine 2014, 9:1883-1889

Published Date: 16 April 2014

Methacrylic-based nanogels for the pH-sensitive delivery of 5-Fluorouracil in the colon

Ashwanikumar N, Kumar NA, Nair SA, Kumar GS

International Journal of Nanomedicine 2012, 7:5769-5779

Published Date: 15 November 2012

Cross-linked acrylic hydrogel for the controlled delivery of hydrophobic drugs in cancer therapy

Deepa G, Thulasidasan AK, Anto RJ, Pillai JJ, Kumar GS

International Journal of Nanomedicine 2012, 7:4077-4088

Published Date: 27 July 2012

Crystallization after intravitreal ganciclovir injection

Pitipol Choopong, Nattaporn Tesavibul, Nattawut Rodanant

Clinical Ophthalmology 2010, 4:709-711

Published Date: 14 July 2010